Kodak received a $765 million loan from the federal government July 28 to expedite domestic drug production and lessen the country’s reliance on foreign suppliers. That loan was put on hold Aug. 7 when the U.S. International Development Finance Corp. tweeted it would not proceed with the Kodak deal until allegations of insider trading were cleared.
DFC’s tweet came after the emergence of Securities and Exchange Commission filings showing Kodak’s executive chair and a Kodak board member had loaded up on shares shortly before the government deal was announced.
“Based on what I’m seeing, what happened at Kodak was probably the dumbest decisions made by executives in corporate history,” Mr. Navarro said during the Aug. 17 interview. “You can’t even anticipate that degree of stupidity.”
The loan will remain on hold as the SEC conducts its investigation into Kodak’s disclosure of the deal. Mr. Navarro told CNBC the White House will focus on other projects associated with its coronavirus response as Kodak is investigated both internally and by the SEC.
More articles on pharmacy:
FDA halts approval of blood plasma as COVID-19 treatment
J&J to acquire Momenta Pharma for $6.5B
US sues Teva for alleged MS drug kickback scheme
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
